Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by narmacon Oct 02, 2022 10:49am
164 Views
Post# 35000142

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingMy 2 cents,,,any PhDs I had an oprtunity to work with over the past years were sincere and interesting people,,,and I grew up beside one,,we have a load of these highly educated people involved and who are hands on with this company. I dont think they intend to embarrass themselves by pushing snake oil technology. Nor do I believe they intentionally mislead us in what the future could hold.

When The Team here say GBS Pll initiated by year end,,,,,and or,,a nasdaq listing is coming within months and also shooting for two Pll trials in 2023, I think they are sincere.

How it transpires is the gamble! But as a run of the mill investor I am taking that chance we actually do make inroads with our science! These next 15 months will hopefully give us an idea of what capabilites our team has and what xB3 can really do against disease.

Bring it on team,,,,,,,and of course we will see BTI to daaaaaaaa moooooooooooooooon!!!!!!!!!,,JMO.
<< Previous
Bullboard Posts
Next >>